Lopinavir/Ritonavir + Grazoprevir (Single Agent) = Prohibited

Effect on Concentration

Lopinavir/Ritonavir
No change
Applies within class?
No
Grazoprevir (Single Agent)
Increase
Applies within class?
No

Pharmacologic Effects

Lopinavir/Ritonavir
Effect
N/A
Applies within class?
No
Grazoprevir (Single Agent)
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 16-Jul-2018

Summary

Sources

Lopinavir/Ritonavir versus Grazoprevir ^

Study Design

In an open-label, 3-period study, 13 healthy subjects with age of 19-55 years old received grazoprevir (GZR, MK-5172) 200 mg once daily for 7 days.1 After a 7-day washout, subjects received lopinavir/ritonavir (LPV/r) 400/100 mg twice daily for 14 days, followed by coadministration of GZR 200 mg daily plus LPV/r 400/100 mg twice daily for 7 days.

Study Results

Coadministration of GZR and LPV/r resulted in significant increase of GZR exposure; geometric mean ratio (GMR; LPV/r + GZR / GZR) [90% CI] of AUC was 12.86 [10.25, 16.13].1 However, there was no significant increase in LPV exposure; GMR (LPV/r+GZR / LPV/r) [90%CI] of AUC was 1.03 [0.92, 1.16].

Study Conclusions

Concomitant use of LPV/r and GZR is not recommended.

References

El-Sherif O, Back D. Drug interactions of hepatitis c direct-acting antivirals in the hiv-infected person. Current Hiv/aids Reports. 2015; 3: 336-343.